PMID- 32810255
OWN - NLM
STAT- MEDLINE
DCOM- 20210216
LR  - 20210216
IS  - 1945-7197 (Electronic)
IS  - 0021-972X (Linking)
VI  - 105
IP  - 12
DP  - 2020 Dec 1
TI  - Management and Appropriate Use of Diazoxide in Infants and Children with 
      Hyperinsulinism.
LID - dgaa543 [pii]
LID - 10.1210/clinem/dgaa543 [doi]
AB  - BACKGROUND: The diagnosis of hypoglycemia and the use of diazoxide have risen in 
      the last decade. Diazoxide is the only Food and Drug Agency-approved 
      pharmacologic treatment for neonatal hypoglycemia caused by hyperinsulinism (HI). 
      Recent publications have highlighted that diazoxide has serious adverse effects 
      (AEs) such as pulmonary hypertension (2-3%) and neutropenia (15%). Despite its 
      increasing use, there is little information regarding dosing of diazoxide and/or 
      monitoring for AEs. METHODS: We convened a working group of pediatric 
      endocrinologists who were members of the Drug and Therapeutics Committee of the 
      Pediatric Endocrine Society (PES) to review the available literature. Our 
      committee sent a survey to its PES members regarding the use of diazoxide in 
      their endocrine practices. Our review of the results concluded that there was 
      substantial heterogeneity in usage and monitoring for AEs for diazoxide among 
      pediatric endocrinologists. CONCLUSIONS: Based on our extensive literature review 
      and on the lack of consensus regarding use of diazoxide noted in our PES survey, 
      our group graded the evidence using the framework of the Grading of 
      Recommendations, Assessment, Development and Evaluation Working Group, and has 
      proposed expert consensus practice guidelines for the appropriate use of 
      diazoxide in infants and children with HI. We summarized the information on AEs 
      reported to date and have provided practical ideas for dosing and monitoring for 
      AEs in infants treated with diazoxide.
CI  - (c) Endocrine Society 2020. All rights reserved. For permissions, please e-mail: 
      journals.permissions@oup.com.
FAU - Brar, Preneet Cheema
AU  - Brar PC
AD  - Division of Endocrinology and Diabetes, Department of Pediatrics, New York 
      University Grossman School of Medicine, New York City, New York.
FAU - Heksch, Ryan
AU  - Heksch R
AD  - Center for Diabetes and Endocrinology, Department of Pediatrics, Akron Children's 
      Hospital, Akron, Ohio.
FAU - Cossen, Kristina
AU  - Cossen K
AD  - Division of Pediatric Endocrinology, Department of Pediatrics, Emory University 
      School of Medicine, Atlanta, Georgia.
FAU - De Leon, Diva D
AU  - De Leon DD
AD  - Division of Endocrinology and Diabetes, Department of Pediatrics, The Children's 
      Hospital of Philadelphia and the Perelman School of Medicine at the University of 
      Pennsylvania, Philadelphia, Pennsylvania.
FAU - Kamboj, Manmohan K
AU  - Kamboj MK
AD  - Division of Endocrinology, Department of Pediatrics, Nationwide Children's 
      Hospital, Columbus, Ohio.
FAU - Marks, Seth D
AU  - Marks SD
AD  - Division of Pediatric Endocrinology and Metabolism, Department of Pediatrics and 
      Child Health, University of Manitoba, Winnipeg, Manitoba, Canada.
FAU - Marshall, Bess A
AU  - Marshall BA
AD  - Division of Endocrinology and Diabetes, Department or Pediatrics, Washington 
      University in St. Louis, St. Louis, Missouri.
FAU - Miller, Ryan
AU  - Miller R
AD  - Division of Pediatric Endocrinology, Department of Pediatrics, University of 
      Maryland School of Medicine, Baltimore, Maryland.
FAU - Page, Laura
AU  - Page L
AD  - Division of Pediatric Endocrinology, Department of Pediatrics, Duke University 
      Medical Center, Durham, North Carolina.
FAU - Stanley, Takara
AU  - Stanley T
AD  - Division of Pediatric Endocrinology, Department of Pediatrics, Massachusetts 
      General Hospital and Harvard Medical School, Boston, Massachusetts.
FAU - Mitchell, Deborah
AU  - Mitchell D
AD  - Division of Pediatric Endocrinology, Department of Pediatrics, Massachusetts 
      General Hospital and Harvard Medical School, Boston, Massachusetts.
FAU - Thornton, Paul
AU  - Thornton P
AD  - Congenital Hyperinsulinism Center, Cook Children's Medical Center, Fort Worth, 
      Texas.
LA  - eng
PT  - Journal Article
PT  - Practice Guideline
PL  - United States
TA  - J Clin Endocrinol Metab
JT  - The Journal of clinical endocrinology and metabolism
JID - 0375362
RN  - 0 (Insulin Antagonists)
RN  - O5CB12L4FN (Diazoxide)
SB  - IM
MH  - Child
MH  - Child, Preschool
MH  - Diazoxide/*adverse effects
MH  - Disease Management
MH  - Female
MH  - Humans
MH  - Hyperinsulinism/*complications
MH  - Hypoglycemia/*drug therapy/etiology
MH  - Infant
MH  - Insulin Antagonists/*adverse effects
MH  - Male
OTO - NOTNLM
OT  - adverse effects
OT  - diazoxide
OT  - hyperinsulinism
OT  - hypoglycemia
OT  - pulmonary hypertension
OT  - thrombocytopenia
EDAT- 2020/08/19 06:00
MHDA- 2021/02/17 06:00
CRDT- 2020/08/19 06:00
PHST- 2020/02/10 00:00 [received]
PHST- 2020/08/11 00:00 [accepted]
PHST- 2020/08/19 06:00 [pubmed]
PHST- 2021/02/17 06:00 [medline]
PHST- 2020/08/19 06:00 [entrez]
AID - 5894029 [pii]
AID - 10.1210/clinem/dgaa543 [doi]
PST - ppublish
SO  - J Clin Endocrinol Metab. 2020 Dec 1;105(12):dgaa543. doi: 10.1210/clinem/dgaa543.